Galectin Therapeutics Inc (GALT) stock
GALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.91−0.11 (-3.64%)
Close on Nov 17, 2026Market cap $293.47MP/E –Yield –
Galectin Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Galectin Therapeutics's total assets was $14.83M at Jun 30, 2026. For fiscal 2025 it was $19.53M, up 11.6% from the year before. Over ten years it grew -3.0% a year on average. The highest annual figure on record is $48.47M in fiscal 2019.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.53M | +11.6% |
| FY2024 | Dec 31, 2024 | $17.50M | -38.0% |
| FY2023 | Dec 31, 2023 | $28.20M | +32.5% |
| FY2022 | Dec 31, 2022 | $21.29M | -49.1% |
| FY2021 | Dec 31, 2021 | $41.83M | +41.3% |
| FY2020 | Dec 31, 2020 | $29.60M | -38.9% |
| FY2019 | Dec 31, 2019 | $48.47M | +438.2% |
| FY2018 | Dec 31, 2018 | $9.01M | +116.4% |
| FY2017 | Dec 31, 2017 | $4.16M | -73.7% |
| FY2016 | Dec 31, 2016 | $15.80M | -40.2% |
| FY2015 | Dec 31, 2015 | $26.41M | -11.0% |
| FY2014 | Dec 31, 2014 | $29.68M | +177.0% |
| FY2013 | Dec 31, 2013 | $10.71M | +12.0% |
| FY2012 | Dec 31, 2012 | $9.56M | +44.6% |
| FY2011 | Dec 31, 2011 | $6.61M | +5.0% |
| FY2010 | Dec 31, 2010 | $6.30M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $14.83M | -5.0% |
| Q1 FY2026 | Mar 31, 2026 | $15.76M | +65.4% |
| Q4 FY2025 | Dec 31, 2025 | $19.53M | +11.6% |
| Q3 FY2025 | Sep 30, 2025 | $12.87M | -55.6% |
| Q2 FY2025 | Jun 30, 2025 | $15.60M | -43.6% |
| Q1 FY2025 | Mar 31, 2025 | $9.53M | -63.2% |
| Q4 FY2024 | Dec 31, 2024 | $17.50M | -38.0% |
| Q3 FY2024 | Sep 30, 2024 | $28.97M | +30.7% |
| Q2 FY2024 | Jun 30, 2024 | $27.66M | +37.7% |
| Q1 FY2024 | Mar 31, 2024 | $25.89M | +28.0% |
| Q4 FY2023 | Dec 31, 2023 | $28.20M | +32.5% |
| Q3 FY2023 | Sep 30, 2023 | $22.16M | +23.7% |
| Q2 FY2023 | Jun 30, 2023 | $20.08M | -22.4% |
| Q1 FY2023 | Mar 31, 2023 | $20.23M | -39.8% |
| Q4 FY2022 | Dec 31, 2022 | $21.29M | -49.1% |
| Q3 FY2022 | Sep 30, 2022 | $17.91M | -52.9% |
| Q2 FY2022 | Jun 30, 2022 | $25.89M | -22.5% |
| Q1 FY2022 | Mar 31, 2022 | $33.62M | +46.8% |
| Q4 FY2021 | Dec 31, 2021 | $41.83M | +41.3% |
| Q3 FY2021 | Sep 30, 2021 | $38.04M | +11.7% |
| Q2 FY2021 | Jun 30, 2021 | $33.41M | -19.1% |
| Q1 FY2021 | Mar 31, 2021 | $22.90M | -48.1% |
| Q4 FY2020 | Dec 31, 2020 | $29.60M | -38.9% |
| Q3 FY2020 | Sep 30, 2020 | $34.05M | -32.9% |
| Q2 FY2020 | Jun 30, 2020 | $41.32M | -22.1% |
| Q1 FY2020 | Mar 31, 2020 | $44.11M | +463.4% |
| Q4 FY2019 | Dec 31, 2019 | $48.47M | +438.2% |
| Q3 FY2019 | Sep 30, 2019 | $50.76M | +378.1% |
| Q2 FY2019 | Jun 30, 2019 | $53.01M | +372.9% |
| Q1 FY2019 | Mar 31, 2019 | $7.83M | +58.8% |
| Q4 FY2018 | Dec 31, 2018 | $9.01M | +116.4% |
| Q3 FY2018 | Sep 30, 2018 | $10.62M | +51.4% |
| Q2 FY2018 | Jun 30, 2018 | $11.21M | +20.2% |
| Q1 FY2018 | Mar 31, 2018 | $4.93M | -64.8% |
| Q4 FY2017 | Dec 31, 2017 | $4.16M | -73.7% |
| Q3 FY2017 | Sep 30, 2017 | $7.01M | -56.5% |
| Q2 FY2017 | Jun 30, 2017 | $9.33M | – |
| Q1 FY2017 | Mar 31, 2017 | $14.00M | – |
| Q4 FY2016 | Dec 31, 2016 | $15.80M | – |
| Q3 FY2016 | Sep 30, 2016 | $16.12M | – |
See a number that looks wrong?